Profile data is unavailable for this security.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcticzymes Technologies ASA | 115.95m | 17.29m | 1.24bn | 68.00 | 72.02 | 4.02 | 52.92 | 10.72 | 0.3443 | 0.3443 | 2.30 | 6.17 | 0.3562 | 0.4228 | 6.29 | 1,731,471.00 | 5.31 | 15.58 | 5.66 | 17.22 | 95.50 | 96.69 | 14.91 | 33.23 | 12.14 | -- | 0.0327 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -128.42m | 1.30bn | 9.00 | -- | 4.85 | -- | -- | -9.96 | -9.96 | 0.00 | 20.59 | 0.00 | -- | -- | 0.00 | -37.63 | -16.11 | -43.78 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Diamyd Medical AB | 282.00k | -120.18m | 1.39bn | 26.00 | -- | 7.53 | -- | 4,937.50 | -1.41 | -1.41 | 0.0033 | 1.91 | 0.0014 | -- | 6.56 | 11,280.00 | -59.77 | -25.46 | -66.19 | -28.37 | -4,930.85 | -1,419.23 | -42,617.73 | -5,896.43 | -- | -130.78 | 0.1176 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Photocure ASA | 504.65m | 4.75m | 1.69bn | 102.00 | 359.65 | 3.54 | 51.67 | 3.34 | 0.1755 | 0.1755 | 19.02 | 17.82 | 0.7215 | 0.9144 | 7.93 | 5,024,010.00 | 0.6789 | -3.06 | 0.7682 | -3.54 | 94.65 | 93.64 | 0.941 | -5.15 | 4.33 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
| Devyser Diagnostics AB | 180.50m | -45.90m | 1.82bn | 124.00 | -- | 4.87 | -- | 10.10 | -2.83 | -2.83 | 11.13 | 23.00 | 0.3671 | 1.56 | 5.11 | 1,529,661.00 | -9.33 | -8.97 | -10.65 | -10.15 | 84.76 | 80.14 | -25.43 | -23.91 | 4.34 | -- | 0.1543 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Nanoform Finland Oyj | 27.26m | -261.34m | 1.83bn | 166.00 | -- | 2.46 | -- | 67.06 | -0.2974 | -0.2974 | 0.031 | 0.774 | 0.0287 | 100.58 | 4.29 | 14,687.82 | -27.47 | -27.13 | -30.12 | -29.48 | -576.50 | -604.26 | -958.65 | -1,023.70 | 6.60 | -- | 0.091 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Genovis AB | 127.01m | 30.68m | 2.02bn | 36.00 | 65.94 | 9.86 | 48.81 | 15.93 | 0.4686 | 0.4686 | 1.94 | 3.13 | 0.5084 | -- | -- | 3,432,784.00 | 12.28 | 18.56 | 13.37 | 21.45 | 66.09 | 65.51 | 24.15 | 23.88 | -- | -- | 0.2769 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
| XSpray Pharma AB (publ) | 0.00 | -212.58m | 2.30bn | 26.00 | -- | 4.19 | -- | -- | -7.66 | -7.66 | 0.00 | 20.00 | 0.00 | -- | -- | 0.00 | -33.92 | -18.38 | -36.11 | -19.26 | -- | -- | -- | -- | 2.24 | -- | 0.0536 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Probi AB | 607.54m | -602.00k | 2.39bn | 167.00 | -- | 1.68 | 24.93 | 3.94 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Egetis Therapeutics AB (publ) | 62.80m | -326.90m | 2.40bn | 30.00 | -- | 5.07 | -- | 38.16 | -1.22 | -1.22 | 0.2326 | 1.62 | 0.0913 | 28.00 | 4.33 | 2,325,926.00 | -47.48 | -33.02 | -53.33 | -36.46 | 82.17 | -- | -520.22 | -357.72 | 2.53 | -144.77 | 0.2014 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| BioInvent International AB | 61.15m | -334.52m | 2.43bn | 109.00 | -- | 1.98 | -- | 39.81 | -5.08 | -5.08 | 0.929 | 18.73 | 0.041 | -- | 1.29 | 550,927.90 | -22.41 | -17.50 | -23.68 | -18.64 | -- | -- | -547.02 | -131.63 | 13.34 | -- | 0.0169 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
| Vicore Pharma Holding AB | 104.24m | -212.94m | 2.46bn | 26.00 | -- | 5.03 | -- | 23.58 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Hansa Biopharma AB | 165.88m | -844.88m | 3.06bn | 166.00 | -- | -- | -- | 18.46 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
Data as of Jun 14 2024. Currency figures normalised to BioInvent International AB's reporting currency: Swedish Krona SEK
36.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 30 Jun 2023 | 10.13m | 15.39% |
| HBM Partners AG (Investment Management)as of 30 Jun 2023 | 5.14m | 7.80% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 4.02m | 6.11% |
| Handelsbanken Fonder ABas of 31 May 2024 | 1.68m | 2.56% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 1.28m | 1.94% |
| E. �hman J :or Fonder ABas of 29 Feb 2024 | 551.07k | 0.84% |
| Rhenman & Partners Asset Management ABas of 30 Jun 2023 | 450.00k | 0.68% |
| Skandia Investment Management ABas of 28 Mar 2024 | 325.96k | 0.50% |
| SEB Investment Management ABas of 30 Apr 2024 | 325.89k | 0.50% |
| FCG Fonder ABas of 31 Dec 2023 | 173.94k | 0.26% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
